The selection of effective chemotherapy drugs that, in combination with targeted mTOR SMI, could be quite well tolerated with minimal toxicity is a priority for ALL treatment, with the aim to define accurate pharmacological protocols and to optimize the drug doses to alleviate adverse effects. This evidence concerns the gene MTOR and acute lymphoblastic leukemia.